Endo Nutshell Issue 2

The Endo Nutshell Series 2 includes a total of four sections. The first section summarizes the findings from a prospective randomized clinical trial which shows the favorable effect of dapagliflozin on endothelial dysfunction in patients with diabetes presenting with atherosclerotic disease.

The next section summarizes the findings from a double-blind, randomized crossover study which explored the effects of dapagliflozin therapy for 5 weeks on 24-h energy balance and substrate metabolism and insulin sensitivity in patients with T2DM. It concluded that dapagliflozin exerts favorable effects on energy metabolism in patients with type 2 diabetes.

The third section discusses the technological advancements in endocrinology and focuses on automated insulin delivery systems for pregnant women with type 1 diabetes.

This series concludes with a highlight from the “American Association of Clinical Endocrinologists AACE Annual Meeting 2021” which was held between 26^th and 29^th May, 2021. Herein, Bhargava A discusses a study that explored the comparative morbidity and mortality in COVID-19 patients with and without diabetes, and concludes that patients with COVID-19 with diabetes present with more severe clinical outcomes than those without diabetes.